Jackie Sim

Dr. Jackie Sim


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2022 in Critical Care
Verified
Journal Article
Open access
PDF file
RLRyan Ruiyang Ling
Ryan Ruiyang Ling
KRKollengode Ramanathan
Kollengode Ramanathan
JSJackie Sim
Jackie Sim
SWSuei Nee Wong
Suei Nee Wong
YCYing Chen
Ying Chen
DBDaniel Brodie
Daniel Brodie
Background: Extracorporeal membrane oxygenation (ECMO) has been used extensively for coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS). Reports early in the pandemic suggested that mortality in patients with COVID-19 receiving ECMO was comparable to non-COVID-19-related ARDS. However, subsequent reports suggested that mortality appeared to be increasing over time. Therefore, we conducted an updated systematic review and meta-analysis, to characterise changes in mortality over time and elucidate risk factors for poor outcomes.Methods: We conducted a meta-analysis (CRD42021271202), searching MEDLINE, Embase, Cochrane, and Scopus databases, from 1 December 2019 to 26 January 2022, for studies reporting on mortality among adults with COVID-19 receiving ECMO. We also captured hospital and intensive care unit lengths of stay, duration of mechanical ventilation and ECMO, as well as complications of ECMO. We conducted random-effects meta-analyses, assessed risk of bias of included studies using the Joanna Briggs Institute checklist and evaluated certainty of pooled estimates using GRADE methodology.Results: Of 4522 citations, we included 52 studies comprising 18,211 patients in the meta-analysis. The pooled mortality rate among patients with COVID-19 requiring ECMO was 48.8% (95% confidence interval 44.8–52.9%, high certainty). Mortality was higher among studies which enrolled patients later in the pandemic as opposed to earlier (1st half 2020: 41.2%, 2nd half 2020: 46.4%, 1st half 2021: 62.0%, 2nd half 2021: 46.5%, interactionpvalue = 0.0014). Predictors of increased mortality included age, the time of final patient enrolment from 1 January 2020, and the proportion of patients receiving corticosteroids, and reduced duration of ECMO run.Conclusions: The mortality rate for patients receiving ECMO for COVID-19-related ARDS has increased as the pandemic has progressed. The reasons for this are likely multifactorial; however, as outcomes for these patients evolve, the decision to initiate ECMO should include the best contextual estimate of mortality at the time of ECMO initiation.

1 March 2022 in The American Journal of Medicine
Verified
Journal Article
Closed access
JSJackie Sim
Jackie Sim
CLCynthia Ciwei Lim
Cynthia Ciwei Lim

27 May 2022 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
JSJackie Sim
Jackie Sim
SMSaikat Mitra
Saikat Mitra
RLRyan Ruiyang Ling
Ryan Ruiyang Ling
CTChuen Seng Tan
Chuen Seng Tan
Bingwen Eugene FanBingwen Eugene Fan
Bingwen Eugene Fan
KRKollengode Ramanathan
Kollengode Ramanathan

11 October 2022 in The American Journal of Cardiology
Verified
Journal Article
Closed access
JSJackie Sim
Jackie Sim
RLRyan Ruiyang Ling
Ryan Ruiyang Ling
VNVernicia Shu Qi Neo
Vernicia Shu Qi Neo
FTFelicia Liying Tan
Felicia Liying Tan
ADAndie Hartanto Djohan
Andie Hartanto Djohan
Ching-Hui SiaChing-Hui Sia
Ching-Hui Sia

13 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HHHuang Huang
Huang Huang
JSJackie Sim
Jackie Sim
HHHla Myint Htoon
Hla Myint Htoon
ACAnnabel Chew
Annabel Chew
RCRachel Chong
Rachel Chong
TWTina T Wong
Tina T Wong
Objectives: We aimed to determine if a 2-week pre-operative course of fluorometholone (FML) eyedrops in chronically medicated glaucoma patients reduces the levels of the pro-inflammatory cytokine Monocyte Chemoattractant Protein 1 (MCP-1) and improves early post-operative outcomes after trabeculectomy or phaco-trabeculectomy. Methods: We conducted a single-center, unmasked, prospective pilot interventional case series of 36 patients with glaucoma who received a 2-week course of FML eyedrops prior to undergoing trabeculectomy. A multiplex bead assay was used to quantify the presence of MCP-1 levels in tear samples before and after the use of FML eyedrops, and 307 eyes without treatment with topical FML served as historical controls. Clinical outcome measures of early post-operative outcomes included IOP and additional post-operative interventions (i.e., needling, glaucoma medications, and surgery) required to achieve the desired IOP at 6 months. Results: Out of 36 patients who received FML, 19 patients had a low MCP-1 level (<250 pg/mL/mg) at baseline, which did not significantly change after using FML, and were excluded from analysis. Of the 17 remaining patients, propensity score-matched analysis was conducted to compare them with 17 patients who did not receive FML, matching for the variables of age, gender, ethnicity, diagnosis, longest glaucoma medication duration, and surgery type. Patients with FML treatment had lower odds of requiring any post-operative intervention (including needling, surgery, or IOP-lowering medications) (OR 0.22, CI 0.049–0.95, p = 0.042) compared to patients who did not have pre-operative FML treatment. Conclusions: In patients with higher levels of MCP-1 pre-operatively, the use of FML for 2 weeks pre-operatively improved their early post-operative outcomes following trabeculectomy or phaco-trabeculectomy.